Banner

Anti-CTLA4 Antibody (RMAB-0250489)

Cat. No.: RMAB-0250489

Category: Primary Antibodies

INQUIRY 100 μL 1 mL
Rabbit monoclonal to CTLA4

Product Features

Isotype IgG
Clonality Monoclonal
Host Species Rabbit
Clone Number CAL49
Form Liquid
Purity Protein A purified
Species Reactivity Human, Mouse
Immunogen Synthetic peptide.
Applications IHC-P, Flow Cyt (Intra), WB, IP
Key Features Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply; Rabbit monoclonal to CTLA4; Suitable for: IHC-P, Flow Cyt (Intra), WB, IP; Reacts with: Mouse, Human

Target Information

Target Symbol CTLA4
Target Name Cytotoxic T-lymphocyte protein 4
UniProt ID P16410
Cellular Localization Cell membrane. Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation and.
Function Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD8 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
Involvement in Disease Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE). SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system.Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12). A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3). It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive.
Post-translational Modifications N-glycosylation is important for dimerization. Phosphorylation at Tyr-21 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.
Sequence Similarities Contains 1 Ig-like V-type (immunoglobulin-like) domain.

Storage & Shipping

Storage Buffer pH: 7.2; Preservative: 0.05% Sodium azide; Constituent: PBS
Storage & Shipping Shipped at 4°C. Store at 4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.

For research use only. Not for clinical use.